Sarepta Therapeutics announces that US FDA has accepted for filing and granted priority review for the biologics license application for SRP-9001, Sarepta’s gene therapy for the treatment of ambulant individuals with Duchenne muscular dystrophy

Sarepta Therapeutics

28 November 2022 - Regulatory action date of 29 May 2023.

Sarepta Therapeutics today announced that the US FDA has accepted the Company's biologics license application seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy.

Read Sarepta Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder